In somatic cancers, including endometrial cancer (UCEC), breast cancer, prostate cancer, and glioblastoma, PTEN inactivation results in missense and nonsense mutation, mono- or bi-allelic deletion of the genomic locus or silencing through promotor methylation [98, 99]. Here, PTEN is linked to prostate cancer.